Abstract: An elevator-calling device and elevator system. The elevator-calling device includes a processor to receive an input instruction and send a signal to a main controller of an elevator system; a display device connected to the processor; a rotatable button, wherein the rotatable button is connected to the processor, and the rotatable button is pressable and rotatable in a first direction and a second direction opposite to the first direction, and wherein the rotatable button has an initial zero scale; and an assistant sound generating unit connected to the processor; wherein the processor is configured to have an assistant elevator-calling mode, in which a preset target floor is increased when the rotatable button rotates in the first direction, the preset target floor is decreased when the rotatable button rotates in the second direction, and the preset target floor is confirmed when the rotatable button is pressed at a non-zero scale.

Abstract: Disclosed is a magnetic pressure retaining control device, which comprises: a valve seat, a magnetic valve cover, and a trigger magnetic member for repelling the magnetic valve cover; the magnetic valve cover and an open end of the valve seat are movably connected; when the magnetic valve cover is in an open state, the trigger magnetic member is opposite to an end surface of the magnetic valve cover away from an inside of the valve seat. A cylindrical magnet is also arranged in the valve seat. By the magnetic between the trigger magnet and the magnetic valve cover, and the magnetic between the magnetic valve cover and the valve seat, a reliable guarantee for the closure between the magnetic valve cover and the valve seat is provided. The valve seat and the valve cover are tightly closed under different conditions.

Abstract: A simulation device for magnetic closing of flap valve is disclosed, which includes a worktable, a driving mechanism for driving the worktable to rotate, a valve seat, a magnetic valve cover movably connected with the valve seat, a first magnet for repelling the magnetic valve cover, a cylinder, a lifting equipment for driving the cylinder to rise and fall. When the cylinder is inserted into the valve seat driven by the lifting equipment, the cylinder prevents the closure of the magnetic valve cover. When the cylinder is out of contact with the magnetic valve cover driven by the lifting equipment, the magnetic valve cover is closed, and the worktable in the simulation device can rotate and turn over, so that the closing process of flap valve (valve seat and valve cover) in any direction of deep drilling coring under the action of magnetic force is simulated.

Abstract: The present application relates to a nitrogen-containing compound, a conjugate containing said compound, and an application thereof. Specifically, the present application provides a compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof. The nitrogen-containing compound has a good regulating effect on TLR8 and can effectively treat, alleviate, and/or prevent various diseases caused by immunosuppression, such as a cancer or a viral infection.

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: The invention provides a transgenic corn event ZM_BCS216090, plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising event ZM_BCS216090. The invention also provides polynucleotides and sequences specific for event ZM_BCS216090 and methods for using plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising event ZM_BCS216090 and detecting event ZM_BCS216090, or a polynucleotide or DNA sequence specific for event ZM_BCS216090, in a DNA molecule or sample.

Abstract: A method for manufacturing the pixel definition layer includes forming a photolithographic material film on a substrate; performing a pre-drying treatment, a first exposure treatment, and a development treatment sequentially on the photolithographic material film to form an initial pattern of the pixel definition layer; and performing a second exposure treatment and a curing treatment sequentially on the initial pattern to form a final pattern of the pixel definition layer.

Abstract: A method for manufacturing the pixel definition layer includes forming a photolithographic material film on a substrate; performing a pre-drying treatment, a first exposure treatment, and a development treatment sequentially on the photolithographic material film to form an initial pattern of the pixel definition layer; and performing a second exposure treatment and a curing treatment sequentially on the initial pattern to form a final pattern of the pixel definition layer.

Abstract: The invention provides recombinant DNA molecules that are unique to maize event MON87429 and transgenic maize plants, maize plant parts, maize seeds, maize cells, and agricultural products containing maize event MON87429 as well as methods of using and detecting maize event MON87429. Transgenic maize plants containing maize event MON87429 exhibit tolerance to inhibitors of acetyl CoA carboxylase (ACCase) in the aryloxyphenoxy propionate (FOP) group, synthetic auxins, inhibitors of glutamine synthetase, and inhibitors of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).

Abstract: The invention provides recombinant DNA molecules that are unique to maize event MON87429 and transgenic maize plants, maize plant parts, maize seeds, maize cells, and agricultural products containing maize event MON87429 as well as methods of using and detecting maize event MON87429. Transgenic maize plants containing maize event MON87429 exhibit tolerance to inhibitors of acetyl CoA carboxylase (ACCase) in the aryloxyphenoxy propionate (FOP) group, synthetic auxins, inhibitors of glutamine synthetase, and inhibitors of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signaling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signaling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.

Abstract: The invention provides recombinant DNA molecules that are unique to maize event MON87429 and transgenic maize plants, maize plant parts, maize seeds, maize cells, and agricultural products containing maize event MON87429 as well as methods of using and detecting maize event MON87429. Transgenic maize plants containing maize event MON87429 exhibit tolerance to inhibitors of acetyl CoA carboxylase (ACCase) in the aryloxyphenoxy propionate (FOP) group, synthetic auxins, inhibitors of glutamine synthetase, and inhibitors of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).

Abstract: Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signaling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signaling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.

Abstract: This invention relates to a kind of C- aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C- aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention relates to a kind of C- aryl glycoside derivatives, it's pharmaceutically acceptable salts or compositions thereof for preparing a SGLT inhibitor. The C- aryl glycoside derivatives of this invention provides a new direction for SGLT inhibitors.

Abstract: This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor.

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.